

Massimo Breccia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7737933/publications.pdf>

Version: 2024-02-01

718
papers

14,060
citations

31902

53
h-index

40881

93
g-index

727
all docs

727
docs citations

727
times ranked

11287
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). <i>Leukemia and Lymphoma</i> , 2022, 63, 189-198. | 0.6 | 3 |
| 2 | COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565. | 1.2 | 20 |
| 3 | Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients. <i>Supportive Care in Cancer</i> , 2022, 30, 4303-4314. | 1.0 | 3 |
| 4 | Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments. <i>Advances in Therapy</i> , 2022, 39, 1101. | 1.3 | 0 |
| 5 | Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-OL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200. | 1.2 | 7 |
| 6 | Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040. | 1.3 | 5 |
| 7 | Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915. | 1.3 | 10 |
| 8 | Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. <i>Annals of Hematology</i> , 2022, 101, 1275-1282. | 0.8 | 2 |
| 9 | Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. <i>Cancer</i> , 2022, 128, 2449-2454. | 2.0 | 7 |
| 10 | Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. <i>Haematologica</i> , 2022, 107, 2356-2364. | 1.7 | 6 |
| 11 | Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2022, 15, 25-32. | 1.0 | 4 |
| 12 | Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical "Biological Entity?". <i>Journal of Clinical Medicine</i> , 2022, 11, 2596. | 1.0 | 0 |
| 13 | Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges. <i>International Journal of Hematology</i> , 2022, 116, 586-593. | 0.7 | 4 |
| 14 | Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 3597. | 1.0 | 8 |
| 15 | Future Management Of Chronic Myeloid Leukemia: From Dose Optimization To New Agents. <i>Current Cancer Drug Targets</i> , 2022, 22, . | 0.8 | 0 |
| 16 | Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group. <i>Leukemia and Lymphoma</i> , 2022, 63, 2751-2753. | 0.6 | 0 |
| 17 | RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort. <i>Blood Advances</i> , 2022, 6, 4424-4426. | 2.5 | 9 |
| 18 | Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. <i>Cell Death and Disease</i> , 2022, 13, . | 2.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. <i>Current Oncology</i> , 2022, 29, 4970-4980. | 0.9 | 2 |
| 20 | A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. <i>Journal of Hematology and Oncology</i> , 2022, 15, . | 6.9 | 18 |
| 21 | Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab. <i>Annals of Hematology</i> , 2021, 100, 2117-2119. | 0.8 | 4 |
| 22 | Therapeutic strategies in low and high-risk MDS: What does the future have to offer?. <i>Blood Reviews</i> , 2021, 45, 100689. | 2.8 | 21 |
| 23 | Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1022-1025. | 0.6 | 2 |
| 24 | Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e328-e333. | 0.2 | 0 |
| 25 | Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678. | 0.6 | 10 |
| 26 | Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study. <i>Leukemia and Lymphoma</i> , 2021, 62, 739-742. | 0.6 | 3 |
| 27 | Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. <i>British Journal of Haematology</i> , 2021, 193, 129-132. | 1.2 | 17 |
| 28 | Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103163. | 2.0 | 10 |
| 29 | Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368. | 1.2 | 19 |
| 30 | Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 237-238. | 1.2 | 0 |
| 31 | Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study. <i>Journal of Palliative Medicine</i> , 2021, 24, 887-893. | 0.6 | 8 |
| 32 | Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021, 62, 1026-1027. | 0.6 | 4 |
| 33 | Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13356. | 1.7 | 6 |
| 34 | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4. | 2.8 | 41 |
| 35 | Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge. <i>Journal of Clinical Medicine</i> , 2021, 10, 515. | 1.0 | 24 |
| 36 | Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Expert Review of Hematology</i> , 2021, 14, 293-302. | 1.0 | 5 |
| 38 | Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 631570. | 1.3 | 5 |
| 39 | American Society of Hematology 2020 Podcast Collection: CML. <i>Advances in Therapy</i> , 2021, 38, 26-30. | 1.3 | 0 |
| 40 | American Society of Hematology 2020 Podcast Collection: MPN. <i>Advances in Therapy</i> , 2021, 38, 16-19. | 1.3 | 0 |
| 41 | Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266. | 0.6 | 0 |
| 42 | Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408. | 0.8 | 8 |
| 43 | Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1213-1219. | 0.8 | 4 |
| 44 | Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Frontiers in Oncology</i> , 2021, 11, 642005. | 1.3 | 11 |
| 45 | New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2280-2283. | 0.6 | 6 |
| 46 | Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665. | 2.0 | 14 |
| 47 | Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021, 35, 1814-1816. | 3.3 | 3 |
| 48 | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. <i>Frontiers in Oncology</i> , 2021, 11, 638689. | 1.3 | 0 |
| 49 | The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e25271. | 0.5 | 4 |
| 50 | Asciminib: an investigational agent for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1-9. | 1.9 | 16 |
| 51 | Measuring prognosis in chronic myeloid leukemia: what's new?. <i>Expert Review of Hematology</i> , 2021, 14, 577-585. | 1.0 | 1 |
| 52 | Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review. <i>Expert Review of Hematology</i> , 2021, 14, 645-654. | 1.0 | 1 |
| 53 | Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171. | 1.3 | 6 |
| 54 | Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S326-S327. | 0.2 | 0 |
| 56 | CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S335-S336. | 0.2 | 0 |
| 57 | Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. <i>Cancers</i> , 2021, 13, 4750. | 1.7 | 8 |
| 58 | The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44. | 2.4 | 11 |
| 59 | Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379. | 2.5 | 5 |
| 60 | Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533. | 0.8 | 2 |
| 61 | Poster: CML-081: Effect of Comorbidities on Response Outcomes With First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S223. | 0.2 | 0 |
| 62 | Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). <i>Annals of Hematology</i> , 2021, 100, 481-485. | 0.8 | 11 |
| 63 | Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014. | 0.8 | 14 |
| 64 | Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial. <i>Blood</i> , 2021, 138, 3603-3603. | 0.6 | 6 |
| 65 | Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 1487-1487. | 0.6 | 0 |
| 66 | Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 3617-3617. | 0.6 | 1 |
| 67 | Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2021, 138, 1283-1283. | 0.6 | 3 |
| 68 | Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1486-1486. | 0.6 | 0 |
| 69 | Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice. <i>Blood</i> , 2021, 138, 4017-4017. | 0.6 | 1 |
| 70 | Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021, 138, 2581-2581. | 0.6 | 1 |
| 71 | Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy. <i>Blood</i> , 2021, 138, 1943-1943. | 0.6 | 0 |
| 72 | First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021, 138, 1474-1474. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. <i>Bone Marrow Transplantation</i> , 2020, 55, 708-716. | 1.3 | 23 |
| 74 | Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166. | 0.8 | 21 |
| 75 | Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918. | 3.3 | 46 |
| 76 | Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498. | 3.3 | 35 |
| 77 | Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. <i>Haematologica</i> , 2020, 105, 1559-1566. | 1.7 | 32 |
| 78 | Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252. | 2.0 | 106 |
| 79 | The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. <i>Leukemia and Lymphoma</i> , 2020, 61, 536-545. | 0.6 | 8 |
| 80 | Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196. | 0.8 | 6 |
| 81 | How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey. <i>Leukemia</i> , 2020, 34, 2805-2808. | 3.3 | 16 |
| 82 | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692. | 1.0 | 2 |
| 83 | Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610. | 0.8 | 1 |
| 84 | Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Clinical Drug Investigation</i> , 2020, 40, 1177-1181. | 1.1 | 2 |
| 85 | Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020, 61, 3476-3483. | 0.6 | 2 |
| 86 | The advantages and risks of ruxolitinib for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2020, 13, 1067-1072. | 1.0 | 8 |
| 87 | On the road to treatment-free remission in chronic myeloid leukemia: what about “the others”? <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1075-1081. | 1.1 | 4 |
| 88 | COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020, 34, 2813-2814. | 3.3 | 16 |
| 89 | A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Philadelphia-negative myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2020, 95, E329-E332. | 2.0 | 14 |
| 90 | Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2405-2416. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. <i>Expert Review of Hematology</i> , 2020, 13, 1311-1318. | 1.0 | 6 |
| 92 | Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020, 105, 286-291. | 1.1 | 2 |
| 93 | Expert opinion on management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. <i>Leukemia</i> , 2020, 34, 1495-1502. | 3.3 | 63 |
| 94 | Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 2773-2777. | 0.8 | 2 |
| 95 | Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530. | 0.8 | 9 |
| 96 | Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66. | 2.8 | 6 |
| 97 | Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 883. | 1.3 | 18 |
| 98 | Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. <i>American Journal of Hematology</i> , 2020, 95, E260-E263. | 2.0 | 15 |
| 99 | Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261. | 3.3 | 57 |
| 100 | Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice. <i>Annals of Hematology</i> , 2020, 99, 65-72. | 0.8 | 13 |
| 101 | High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146. | 0.7 | 2 |
| 102 | Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. <i>British Journal of Haematology</i> , 2020, 190, e304-e307. | 1.2 | 1 |
| 103 | Direct oral anticoagulants in patients with hematologic malignancies. <i>Hematological Oncology</i> , 2020, 38, 589-596. | 0.8 | 8 |
| 104 | Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached. <i>EClinicalMedicine</i> , 2020, 19, 100277. | 3.2 | 5 |
| 105 | The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459. | 3.3 | 14 |
| 106 | First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an operational cure. <i>Lancet Haematology</i> , 2020, 7, e182-e183. | 2.2 | 0 |
| 107 | Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380. | 0.8 | 15 |
| 108 | Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1199-1209. | 0.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian medicines agency (AIFA). <i>Cancer Medicine</i> , 2020, 9, 4160-4165. | 1.3 | 32 |
| 110 | Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group". <i>European Journal of Haematology</i> , 2020, 105, 335-343. | 1.1 | 8 |
| 111 | Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002281. | 0.8 | 1 |
| 112 | Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". <i>Blood</i> , 2020, 136, 35-36. | 0.6 | 1 |
| 113 | Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. <i>Blood</i> , 2020, 136, 47-50. | 0.6 | 37 |
| 114 | Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020, 136, 43-44. | 0.6 | 2 |
| 115 | Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020062. | 0.5 | 11 |
| 116 | Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48. | 0.6 | 0 |
| 117 | Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020, 136, 17-18. | 0.6 | 1 |
| 118 | Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46. | 0.6 | 1 |
| 119 | Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9. | 0.6 | 0 |
| 120 | Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50. | 0.6 | 0 |
| 121 | Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION. <i>Blood</i> , 2020, 136, 31-32. | 0.6 | 1 |
| 122 | First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020, 136, 43-44. | 0.6 | 0 |
| 123 | Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338. | 0.8 | 17 |
| 124 | Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265. | 2.0 | 56 |
| 125 | TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019025. | 0.5 | 7 |
| 126 | Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019, 37, 652-654. | 0.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S289-S290. | 0.2 | 0 |
| 128 | Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S290-S291. | 0.2 | 5 |
| 129 | Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019, 42, 660-664. | 0.8 | 2 |
| 130 | A journey through infectious risk associated with ruxolitinib. <i>British Journal of Haematology</i> , 2019, 187, 286-295. | 1.2 | 28 |
| 131 | Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S287-S288. | 0.2 | 4 |
| 132 | Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936. | 0.8 | 5 |
| 133 | Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019, 98, 1919-1925. | 0.8 | 8 |
| 134 | Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. <i>American Journal of Hematology</i> , 2019, 94, E239-E242. | 2.0 | 3 |
| 135 | Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data. <i>Acta Haematologica</i> , 2019, 142, 61-63. | 0.7 | 0 |
| 136 | Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019, 98, 1891-1904. | 0.8 | 10 |
| 137 | Treatment of Philadelphia \neg negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295. | 0.8 | 14 |
| 138 | Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890. | 0.8 | 10 |
| 139 | Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127. | 0.8 | 19 |
| 140 | Management and outcome of 11 pregnancies in women with polycythemia vera. <i>Leukemia Research</i> , 2019, 81, 25-26. | 0.4 | 2 |
| 141 | Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423. | 0.8 | 3 |
| 142 | Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302. | 0.8 | 53 |
| 143 | Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596. | 1.7 | 58 |
| 144 | Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071982644. | 1.1 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290. | 2.5 | 66 |
| 146 | Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131. | 6.9 | 45 |
| 147 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019, 381, 2315-2326. | 13.9 | 257 |
| 148 | Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1598-1607. | 3.3 | 15 |
| 149 | Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. <i>Leukemia Research</i> , 2019, 76, 65-69. | 0.4 | 8 |
| 150 | Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 81-87. | 1.0 | 11 |
| 151 | Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896. | 0.8 | 10 |
| 152 | Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial. <i>Blood</i> , 2019, 134, 1652-1652. | 0.6 | 3 |
| 153 | Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. <i>Blood</i> , 2019, 134, 4145-4145. | 0.6 | 3 |
| 154 | Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. <i>Blood</i> , 2019, 134, 1649-1649. | 0.6 | 7 |
| 155 | Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839. | 0.6 | 2 |
| 156 | Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18220-e18220. | 0.8 | 0 |
| 157 | Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23073-e23073. | 0.8 | 0 |
| 158 | Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166. | 0.6 | 0 |
| 159 | Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4188-4188. | 0.6 | 0 |
| 160 | Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010. | 0.6 | 0 |
| 161 | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Blood</i> , 2019, 134, 4153-4153. | 0.6 | 0 |
| 162 | Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4174-4174. | 0.6 | 2 |
| 164 | Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4179-4179. | 0.6 | 1 |
| 165 | Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019, 134, 3845-3845. | 0.6 | 1 |
| 166 | Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial. <i>Blood</i> , 2019, 134, 4155-4155. | 0.6 | 1 |
| 167 | Treatment-free remission in chronic myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 686-696. | 0.3 | 6 |
| 168 | Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2018, 20, 23. | 1.8 | 19 |
| 169 | Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. <i>Annals of Hematology</i> , 2018, 97, 745-754. | 0.8 | 11 |
| 170 | Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian “Back to Life” project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554. | 1.5 | 9 |
| 171 | Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237. | 2.0 | 22 |
| 172 | Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580. | 0.8 | 32 |
| 173 | Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569. | 0.8 | 46 |
| 174 | Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018, 69, 18-23. | 0.4 | 2 |
| 175 | Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161. | 2.0 | 26 |
| 176 | Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option. <i>Clinical Drug Investigation</i> , 2018, 38, 475-476. | 1.1 | 19 |
| 177 | Special Situations in APL. , 2018, , 203-210. | | 0 |
| 178 | Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy. <i>Expert Review of Hematology</i> , 2018, 11, 301-306. | 1.0 | 8 |
| 179 | Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2018, 181, 275-278. | 1.2 | 3 |
| 180 | Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. <i>British Journal of Haematology</i> , 2018, 181, 267-270. | 1.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Comparison of <i>JAK2</i> ^{V617F} -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018, 36, 269-275. | 0.8 | 11 |
| 182 | Efficacy and safety of ruxolitinib in intermediate- to high-risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290. | 0.8 | 29 |
| 183 | Association between proteomic profile and molecular response in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1016-1018. | 0.6 | 0 |
| 184 | Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100. | 0.8 | 32 |
| 185 | Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259. | 2.0 | 31 |
| 186 | Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2018, 182, 427-429. | 1.2 | 8 |
| 187 | Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88. | 0.4 | 23 |
| 188 | Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S223. | 0.2 | 0 |
| 189 | Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018, 97, 1803-1808. | 0.8 | 18 |
| 190 | Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 623-628. | 1.0 | 10 |
| 191 | Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018, 97, 1797-1802. | 0.8 | 20 |
| 192 | Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194. | 1.3 | 84 |
| 193 | Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46. | 1.2 | 7 |
| 194 | Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91. | 0.4 | 2 |
| 195 | Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255. | 1.8 | 24 |
| 196 | Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018, 101, 578-584. | 1.1 | 3 |
| 197 | Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 1767-1774. | 0.8 | 15 |
| 198 | Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018, 132, 3006-3006. | 0.6 | 1 |
| 200 | Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. <i>Blood</i> , 2018, 132, 792-792. | 0.6 | 8 |
| 201 | Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277. | 0.6 | 11 |
| 202 | Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. <i>Blood</i> , 2018, 132, 45-45. | 0.6 | 4 |
| 203 | One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018, 132, 1732-1732. | 0.6 | 1 |
| 204 | The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44. | 0.6 | 8 |
| 205 | International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. <i>Blood</i> , 2018, 132, 1750-1750. | 0.6 | 6 |
| 206 | Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458. | 0.6 | 3 |
| 207 | Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018, 9, 7534-7540. | 0.8 | 19 |
| 208 | Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018, 9, 21758-21769. | 0.8 | 3 |
| 209 | Ponatinib: A Review of Efficacy and Safety. <i>Current Cancer Drug Targets</i> , 2018, 18, 847-856. | 0.8 | 57 |
| 210 | Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7081-TPS7081. | 0.8 | 1 |
| 211 | Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018, 132, 1746-1746. | 0.6 | 0 |
| 212 | Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052. | 0.6 | 0 |
| 213 | Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018, 132, 5518-5518. | 0.6 | 0 |
| 214 | Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018, 132, 1741-1741. | 0.6 | 0 |
| 215 | Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018, 132, 5516-5516. | 0.6 | 0 |
| 216 | Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018, 132, 4312-4312. | 0.6 | 0 |
| 218 | Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera. <i>Blood</i> , 2018, 132, 5471-5471. | 0.6 | 0 |
| 219 | Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021. | 0.6 | 0 |
| 220 | Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018, 132, 5464-5464. | 0.6 | 0 |
| 221 | Impact of exclusion criteria for the DASISION and ENESTnd trials in the frontâ€line treatment of a realâ€lifeâ€™ patient population with chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2017, 35, 232-236. | 0.8 | 13 |
| 222 | Ironâ€chelating therapy with deferasirox in transfusionâ€dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017, 177, 741-750. | 1.2 | 23 |
| 223 | The BCRâ€ABL1 transcript type influences response and outcome in Philadelphia chromosomeâ€positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805. | 2.0 | 71 |
| 224 | Second line small molecule therapy options for treating chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 57-65. | 0.9 | 8 |
| 225 | Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536. | 1.7 | 15 |
| 226 | Are chronic myeloid leukemia patients ready to stop long-term treatment?. <i>Leukemia and Lymphoma</i> , 2017, 58, 2976-2978. | 0.6 | 2 |
| 227 | Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. <i>Cancer Medicine</i> , 2017, 6, 1233-1239. | 1.3 | 9 |
| 228 | A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with â‰¥30% blasts. <i>Leukemia</i> , 2017, 31, 2799-2806. | 3.3 | 59 |
| 229 | How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. <i>Expert Review of Hematology</i> , 2017, 10, 155-159. | 1.0 | 8 |
| 230 | Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S313-S314. | 0.2 | 1 |
| 231 | Association between Proteomic Profile and Molecular Response (MR) in Chronic Myeloid Leukemia (CML) Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S312. | 0.2 | 0 |
| 232 | Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the realâ€life. <i>American Journal of Hematology</i> , 2017, 92, E668-E670. | 2.0 | 7 |
| 233 | Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1001-1008. | 1.5 | 13 |
| 234 | The Eutos longâ€term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, E661-E664. | 2.0 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. <i>Thrombosis Research</i> , 2017, 156, 168-171. | 0.8 | 9 |
| 236 | Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , 2017, 96, 549-558. | 0.8 | 48 |
| 237 | Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41. | 2.0 | 62 |
| 238 | Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612. | 0.8 | 299 |
| 239 | Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 804-809. | 0.8 | 5 |
| 240 | Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. <i>Annals of Hematology</i> , 2017, 96, 387-391. | 0.8 | 14 |
| 241 | Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 204. | 1.0 | 0 |
| 242 | Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086. | 0.8 | 63 |
| 243 | A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046. | 0.5 | 3 |
| 244 | Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. <i>European Journal of Haematology</i> , 2016, 96, 643-649. | 1.1 | 19 |
| 245 | Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622. | 2.0 | 10 |
| 246 | Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351. | 1.1 | 31 |
| 247 | Current first- and second-line treatment options in acute promyelocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2016, 5, 105-118. | 0.7 | 5 |
| 248 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. <i>Leukemia</i> , 2016, 30, 1648-1671. | 3.3 | 369 |
| 249 | PML-RAR α kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. <i>Leukemia</i> , 2016, 30, 1987-1992. | 3.3 | 75 |
| 250 | Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?. <i>Current Medical Research and Opinion</i> , 2016, 32, 1453-1454. | 0.9 | 2 |
| 251 | Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a Gruppo Romano Mielodisplasie (GROM) multicenter study. <i>Annals of Hematology</i> , 2016, 95, 1059-1065. | 0.8 | 7 |
| 252 | Frontline Dasatinib Treatment in a Real-Life Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540. | 2.3 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2016, 173, 945-946. | 1.2 | 6 |
| 254 | Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016, 174, 160-162. | 1.2 | 7 |
| 255 | Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. <i>Haematologica</i> , 2016, 101, e267-e268. | 1.7 | 7 |
| 256 | Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. <i>Supportive Care in Cancer</i> , 2016, 24, 4887-4894. | 1.0 | 18 |
| 257 | Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. <i>Leukemia Research</i> , 2016, 48, 20-25. | 0.4 | 11 |
| 258 | Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 190-198. | 2.0 | 15 |
| 259 | Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207. | 1.7 | 22 |
| 260 | Current standard treatment of adult acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 841-854. | 1.2 | 60 |
| 261 | Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. <i>Supportive Care in Cancer</i> , 2016, 24, 4487-4493. | 1.0 | 9 |
| 262 | How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1517-1526. | 0.9 | 1 |
| 263 | Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. <i>American Journal of Hematology</i> , 2016, 91, 318-321. | 2.0 | 28 |
| 264 | Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. <i>Leukemia and Lymphoma</i> , 2016, 57, 99-102. | 0.6 | 13 |
| 265 | Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 525-533. | 1.0 | 10 |
| 266 | The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 211-219. | 0.8 | 18 |
| 267 | Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 376-388. | 2.0 | 15 |
| 268 | Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29. | 0.4 | 6 |
| 269 | Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 1128-1128. | 0.6 | 4 |
| 270 | Incidence of Severe ($\geq 10g/dl$) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. <i>Blood</i> , 2016, 128, 1903-1903. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN. <i>Blood</i> , 2016, 128, 1951-1951. | 0.6 | 3 |
| 272 | Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy. <i>Blood</i> , 2016, 128, 2415-2415. | 0.6 | 3 |
| 273 | Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. <i>Blood</i> , 2016, 128, 3068-3068. | 0.6 | 1 |
| 274 | Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016, 128, 3070-3070. | 0.6 | 10 |
| 275 | Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016, 128, 4251-4251. | 0.6 | 2 |
| 276 | Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA. <i>Blood</i> , 2016, 128, 448-448. | 0.6 | 3 |
| 277 | Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. <i>Blood</i> , 2016, 128, 625-625. | 0.6 | 20 |
| 278 | Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. <i>Blood</i> , 2016, 128, 942-942. | 0.6 | 2 |
| 279 | Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090. | 0.8 | 24 |
| 280 | Chronic Myeloid Leukemia. , 2016, , 1059-1063. | | 0 |
| 281 | The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2016, 128, 3097-3097. | 0.6 | 0 |
| 282 | Physicians' Attitude Towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2016, 128, 5939-5939. | 0.6 | 0 |
| 283 | Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 1242-1242. | 0.6 | 0 |
| 284 | Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016, 128, 5464-5464. | 0.6 | 0 |
| 285 | Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN. <i>Blood</i> , 2016, 128, 5473-5473. | 0.6 | 0 |
| 286 | Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. <i>Blood</i> , 2016, 128, 5544-5544. | 0.6 | 1 |
| 287 | Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. <i>Blood</i> , 2016, 128, 5469-5469. | 0.6 | 0 |
| 288 | Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2016, 128, 5465-5465. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016, 128, 3078-3078. | 0.6 | 0 |
| 290 | Ponatinib in chronic myeloid leukaemia: ready for first-line?. <i>Lancet Haematology</i> , 2015, 2, e352-e353. | 2.2 | 0 |
| 291 | Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. <i>American Journal of Hematology</i> , 2015, 90, 105-108. | 2.0 | 10 |
| 292 | Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. <i>Clinical Investigation</i> , 2015, 5, 257-265. | 0.0 | 1 |
| 293 | Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015, 90, E181-2. | 2.0 | 2 |
| 294 | Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. <i>Hematological Oncology</i> , 2015, 33, 48-51. | 0.8 | 3 |
| 295 | Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. <i>American Journal of Hematology</i> , 2015, 90, E100-1. | 2.0 | 14 |
| 296 | Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015, 23, 3289-3295. | 1.0 | 39 |
| 297 | Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?. <i>Expert Review of Hematology</i> , 2015, 8, 387-389. | 1.0 | 7 |
| 298 | Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach. <i>Expert Review of Hematology</i> , 2015, 8, 5-7. | 1.0 | 4 |
| 299 | Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015, 56, 2206-2207. | 0.6 | 6 |
| 300 | FLT3-ITD in acute promyelocytic leukemia: Clinical distinct profile but still controversial prognosis. <i>Leukemia Research</i> , 2015, 39, 397-399. | 0.4 | 20 |
| 301 | Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. <i>Annals of Hematology</i> , 2015, 94, 195-200. | 0.8 | 15 |
| 302 | Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5. | 2.0 | 93 |
| 303 | Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 314-317. | 0.4 | 11 |
| 304 | Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192. | 0.6 | 72 |
| 305 | Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015, 90, E95-E96. | 2.0 | 0 |
| 306 | Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome – Emphasis on optimized dosing schedules and new formulations. <i>Leukemia Research</i> , 2015, 39, 1028-1033. | 0.4 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. <i>Annals of Hematology</i> , 2015, 94, 771-777. | 0.8 | 25 |
| 308 | Deferasirox chelation therapy in patients with transfusion-dependent MDS: a real-world report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015, 95, 52-56. | 1.1 | 22 |
| 309 | Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. <i>Leukemia</i> , 2015, 29, 1084-1091. | 3.3 | 70 |
| 310 | The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Acta Haematologica</i> , 2015, 134, 57-58. | 0.7 | 0 |
| 311 | Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349. | 3.3 | 62 |
| 312 | Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150. | 1.7 | 39 |
| 313 | Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. <i>Blood Cancer Journal</i> , 2015, 5, e347-e347. | 2.8 | 29 |
| 314 | Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015, 29, 1823-1831. | 3.3 | 77 |
| 315 | Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline. <i>British Journal of Haematology</i> , 2015, 169, 148-150. | 1.2 | 17 |
| 316 | Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514. | 5.1 | 76 |
| 317 | Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059. | 0.4 | 57 |
| 318 | Bosutinib for Chronic Myeloid Leukemia. <i>Rare Cancers and Therapy</i> , 2015, 3, 35-46. | 0.2 | 4 |
| 319 | Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia. <i>Rare Cancers and Therapy</i> , 2015, 3, 119-132. | 0.2 | 6 |
| 320 | Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 859-865. | 0.4 | 17 |
| 321 | Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. <i>Annals of Hematology</i> , 2015, 94, 393-397. | 0.8 | 62 |
| 322 | Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes. <i>Diabetes</i> , 2015, 7, 493-496. | 0.8 | 0 |
| 323 | Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370. | 1.2 | 59 |
| 324 | Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015, 126, 1606-1606. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. <i>Blood</i> , 2015, 126, 2792-2792. | 0.6 | 2 |
| 326 | Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. <i>Blood</i> , 2015, 126, 2799-2799. | 0.6 | 6 |
| 327 | Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. <i>Blood</i> , 2015, 126, 4038-4038. | 0.6 | 1 |
| 328 | Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. <i>Blood</i> , 2015, 126, 2099-2099. | 0.6 | 0 |
| 329 | JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. <i>Blood</i> , 2015, 126, 1614-1614. | 0.6 | 0 |
| 330 | Bone Marrow (BM) Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. <i>Blood</i> , 2015, 126, 1570-1570. | 0.6 | 0 |
| 331 | The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. <i>Blood</i> , 2015, 126, 2815-2815. | 0.6 | 0 |
| 332 | Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015, 126, 1582-1582. | 0.6 | 0 |
| 333 | Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. <i>Blood</i> , 2015, 126, 4046-4046. | 0.6 | 0 |
| 334 | Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. <i>Blood</i> , 2015, 126, 2811-2811. | 0.6 | 4 |
| 335 | Application of the International Prognostic Score of Thrombosis for Essential Thrombocythemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. <i>Blood</i> , 2015, 126, 2821-2821. | 0.6 | 1 |
| 336 | Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015, 126, 1598-1598. | 0.6 | 0 |
| 337 | EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014011. | 0.5 | 10 |
| 338 | Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib. <i>Leukemia and Lymphoma</i> , 2014, 55, 204-206. | 0.6 | 1 |
| 339 | Patient-reported outcomes in acute leukemia: a roadmap for future research. <i>European Journal of Haematology</i> , 2014, 93, 86-87. | 1.1 | 1 |
| 340 | How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review. <i>Leukemia Research</i> , 2014, 38, 1392-1398. | 0.4 | 43 |
| 341 | Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1621-1630. | 0.9 | 3 |
| 342 | ATRA + ATO. <i>Current Opinion in Hematology</i> , 2014, 21, 95-101. | 1.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014003. | 0.5 | 22 |
| 344 | Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014, 25, 447-454. | 0.6 | 38 |
| 345 | Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2014, 38, 294-298. | 0.4 | 32 |
| 346 | Validation of a new proposed relapse risk score (CBC-score) for acute promyelocytic leukaemia. <i>International Journal of Hematology</i> , 2014, 99, 100-101. | 0.7 | 1 |
| 347 | Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). <i>BioDrugs</i> , 2014, 28, 17-26. | 2.2 | 24 |
| 348 | Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia. <i>Cancer Letters</i> , 2014, 347, 22-28. | 3.2 | 16 |
| 349 | Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014, 93, 1413-1420. | 0.8 | 7 |
| 350 | Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014, 89, 565-565. | 2.0 | 2 |
| 351 | Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124. | 2.0 | 14 |
| 352 | Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients. <i>American Journal of Hematology</i> , 2014, 89, 542-546. | 2.0 | 33 |
| 353 | Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 3406-3412. | 0.8 | 76 |
| 354 | Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176. | 0.4 | 30 |
| 355 | Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?. <i>Annals of Hematology</i> , 2014, 93, 1951-1952. | 0.8 | 24 |
| 356 | Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Annals of Hematology</i> , 2014, 93, 1819-1823. | 0.8 | 23 |
| 357 | International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. <i>Quality of Life Research</i> , 2014, 23, 825-836. | 1.5 | 67 |
| 358 | Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. <i>British Journal of Haematology</i> , 2014, 167, 428-430. | 1.2 | 6 |
| 359 | Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014, 38, 194-197. | 0.4 | 23 |
| 360 | Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 181-189. | 2.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 361 | Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. <i>Thrombosis Research</i> , 2014, 133, S112-S116. | 0.8 | 41 |
| 362 | Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> . 2013;121(26):5138-5144.. <i>Blood</i> , 2014, 123, 2902-2902. | 0.6 | 0 |
| 363 | Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia “ Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , 2014, 124, 12-12. | 0.6 | 5 |
| 364 | Chronic Myeloid Leukemia. , 2014, , 1-5. | | 0 |
| 365 | Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycythemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up. <i>Blood</i> , 2014, 124, 1855-1855. | 0.6 | 0 |
| 366 | Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. <i>Blood</i> , 2014, 124, 4532-4532. | 0.6 | 0 |
| 367 | “Real-life” Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5530-5530. | 0.6 | 0 |
| 368 | Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+ CML. <i>Blood</i> , 2014, 124, 1794-1794. | 0.6 | 1 |
| 369 | Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3687-3687. | 0.6 | 0 |
| 370 | Systematic Coronary Risk Evaluation (SCORE) Chart Identify Chronic Myeloid Leukemia Patients at Risk of Cardiovascular Diseases during Nilotinib Treatment. <i>Blood</i> , 2014, 124, 4545-4545. | 0.6 | 0 |
| 371 | Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014, 124, 3265-3265. | 0.6 | 0 |
| 372 | Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1063-1063. | 0.6 | 0 |
| 373 | Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. <i>Blood</i> , 2014, 124, 3141-3141. | 0.6 | 10 |
| 374 | Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects. <i>Blood</i> , 2014, 124, 5326-5326. | 0.6 | 0 |
| 375 | Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2014, 124, 3189-3189. | 0.6 | 0 |
| 376 | Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. <i>Blood Transfusion</i> , 2014, 12 Suppl 1, s162-3. | 0.3 | 4 |
| 377 | Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013, 31, 103-109. | 0.8 | 59 |
| 378 | Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121. | 13.9 | 1,284 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 379 | Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637. | 1.3 | 36 |
| 380 | Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the Elderly. <i>Drugs and Aging</i> , 2013, 30, 467-477. | 1.3 | 3 |
| 381 | Imatinib induces body mass changes in women with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 1581-1582. | 0.8 | 4 |
| 382 | Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation. <i>Annals of Hematology</i> , 2013, 92, 1413-1414. | 0.8 | 3 |
| 383 | Efficacy and safety of deferasirox in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2013, 92, 863-870. | 0.8 | 28 |
| 384 | Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 179-183. | 0.8 | 12 |
| 385 | Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013, 92, 25-32. | 0.8 | 23 |
| 386 | Are there real benefits of hypomethylating agents for therapy-related myeloid neoplasms?. <i>Leukemia Research</i> , 2013, 37, 485-486. | 0.4 | 0 |
| 387 | Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1786-1787. | 0.6 | 8 |
| 388 | Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. <i>Annals of Hematology</i> , 2013, 92, 411-412. | 0.8 | 15 |
| 389 | Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far?. <i>Leukemia Research</i> , 2013, 37, 204-205. | 0.4 | 6 |
| 390 | Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465. | 0.6 | 29 |
| 391 | Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. <i>Cancer Letters</i> , 2013, 333, 32-35. | 3.2 | 19 |
| 392 | The role of comorbidities in chronic myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 729-730. | 0.4 | 7 |
| 393 | “To switch or not to switch: That is the question” More than 10% of ratio @ 3 months: How to treat chronic myeloid leukemia patients with this response?. <i>Leukemia Research</i> , 2013, 37, 995-997. | 0.4 | 1 |
| 394 | The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients. <i>Leukemia Research</i> , 2013, 37, 1436-1437. | 0.4 | 0 |
| 395 | Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2013, 37, 713-720. | 0.4 | 33 |
| 396 | Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348. | 1.1 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. <i>Leukemia Research</i> , 2013, 37, 383-385. | 0.4 | 3 |
| 398 | The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?. <i>Leukemia and Lymphoma</i> , 2013, 54, 669-670. | 0.6 | 1 |
| 399 | High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 658-661. | 0.6 | 54 |
| 400 | MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013045. | 0.5 | 6 |
| 401 | Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2013, 129, 126-134. | 0.7 | 5 |
| 402 | Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization. <i>Leukemia and Lymphoma</i> , 2013, 54, 411-412. | 0.6 | 4 |
| 403 | Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. <i>Leukemia</i> , 2013, 27, 1511-1519. | 3.3 | 119 |
| 404 | Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2671-2677. | 0.8 | 121 |
| 405 | Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144. | 0.6 | 49 |
| 406 | The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. <i>Blood</i> , 2013, 121, 4439-4442. | 0.6 | 546 |
| 407 | Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, 399-403. | 1.7 | 42 |
| 408 | FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. <i>Haematologica</i> , 2013, 98, e161-e163. | 1.7 | 49 |
| 409 | Systematic review of dasatinib in chronic myeloid leukemia. <i>OncoTargets and Therapy</i> , 2013, 6, 257. | 1.0 | 12 |
| 410 | Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE). <i>Blood</i> , 2013, 122, 1406-1406. | 0.6 | 2 |
| 411 | Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. <i>Blood</i> , 2013, 122, 258-258. | 0.6 | 2 |
| 412 | Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a "Real-life" Patient Population With Chronic Myelogenous Leukemia?. <i>Blood</i> , 2013, 122, 4002-4002. | 0.6 | 1 |
| 413 | Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013, 122, 770-770. | 0.6 | 2 |
| 414 | The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. <i>Blood</i> , 2013, 122, 1486-1486. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | 4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. <i>Blood</i> , 2013, 122, 4000-4000. | 0.6 | 0 |
| 416 | FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. <i>Blood</i> , 2013, 122, 1336-1336. | 0.6 | 0 |
| 417 | Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. <i>Blood</i> , 2013, 122, 2659-2659. | 0.6 | 0 |
| 418 | Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. <i>Blood</i> , 2013, 122, 5229-5229. | 0.6 | 0 |
| 419 | Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2013, 122, 1594-1594. | 0.6 | 0 |
| 420 | Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. <i>Blood</i> , 2013, 122, 5203-5203. | 0.6 | 0 |
| 421 | 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. <i>Leukemia and Lymphoma</i> , 2012, 53, 1558-1560. | 0.6 | 16 |
| 422 | Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. <i>Blood</i> , 2012, 119, 49-54. | 0.6 | 63 |
| 423 | Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. <i>Haematologica</i> , 2012, 97, 1731-1735. | 1.7 | 22 |
| 424 | Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. <i>Leukemia and Lymphoma</i> , 2012, 53, 985-986. | 0.6 | 20 |
| 425 | Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. <i>Haematologica</i> , 2012, 97, 560-567. | 1.7 | 61 |
| 426 | Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients. <i>Current Cancer Drug Targets</i> , 2012, 12, 391-401. | 0.8 | 3 |
| 427 | MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine. <i>Haematologica</i> , 2012, 97, e2-e2. | 1.7 | 20 |
| 428 | Suboptimal response in chronic myeloid leukemia patients treated with imatinib: Early identification and new therapeutic challenges. <i>Cancer Letters</i> , 2012, 325, 18-25. | 3.2 | 1 |
| 429 | Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2073-2074. | 0.6 | 0 |
| 430 | Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. <i>British Journal of Cancer</i> , 2012, 107, 904-909. | 2.9 | 100 |
| 431 | Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?. <i>Annals of Hematology</i> , 2012, 91, 1371-1381. | 0.8 | 51 |
| 432 | How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages. <i>Cancer Letters</i> , 2012, 322, 127-132. | 3.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44. | 6.9 | 49 |
| 434 | Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 0-0. | 1.2 | 6 |
| 435 | The EUTOS score identifies chronic myeloid leukemia patients with poor prognosis treated with imatinib first or second line. <i>Leukemia Research</i> , 2012, 36, e209-e210. | 0.4 | 19 |
| 436 | Can we safely discontinue imatinib? Searching for new endpoints in CML: A standardized definition of "cure". <i>Leukemia Research</i> , 2012, 36, 1498-1499. | 0.4 | 3 |
| 437 | Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 2439-2443. | 0.6 | 6 |
| 438 | Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1031-1043. | 0.9 | 46 |
| 439 | Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFR ² rearrangement and type 1 diabetes. <i>Annals of Hematology</i> , 2012, 91, 1823-1824. | 0.8 | 14 |
| 440 | Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 497-498. | 0.6 | 6 |
| 441 | Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. <i>Annals of Hematology</i> , 2012, 91, 1345-1349. | 0.8 | 31 |
| 442 | Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 93-100. | 2.0 | 29 |
| 443 | Evaluation of residual CD34 ⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. <i>Cancer</i> , 2012, 118, 5265-5269. | 2.0 | 13 |
| 444 | Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 123-135. | 2.0 | 26 |
| 445 | Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. <i>Leukemia Research</i> , 2012, 36, e66-e67. | 0.4 | 24 |
| 446 | Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2012, 36, 546-547. | 0.4 | 3 |
| 447 | Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies. <i>Leukemia Research</i> , 2012, 36, 682-683. | 0.4 | 1 |
| 448 | Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2012, 36, 804-805. | 0.4 | 12 |
| 449 | Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who's afraid of the big bad wolf?. <i>Leukemia Research</i> , 2012, 36, 813-814. | 0.4 | 9 |
| 450 | Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Cancer</i> , 2012, 118, 404-409. | 2.0 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. <i>Annals of Hematology</i> , 2012, 91, 309-310. | 0.8 | 4 |
| 452 | The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. <i>Blood</i> , 2012, 120, 1678-1678. | 0.6 | 14 |
| 453 | The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2012, 120, 1680-1680. | 0.6 | 5 |
| 454 | Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. <i>Blood</i> , 2012, 120, 1686-1686. | 0.6 | 12 |
| 455 | Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. <i>Blood</i> , 2012, 120, 3784-3784. | 0.6 | 5 |
| 456 | ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSC. <i>Blood</i> , 2012, 120, 6-6. | 0.6 | 18 |
| 457 | The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. <i>Blood</i> , 2012, 120, 5062-5062. | 0.6 | 0 |
| 458 | Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. <i>Blood</i> , 2012, 120, 4958-4958. | 0.6 | 0 |
| 459 | Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. <i>Blood</i> , 2012, 120, 4951-4951. | 0.6 | 0 |
| 460 | Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.. <i>Blood</i> , 2012, 120, 2784-2784. | 0.6 | 0 |
| 461 | Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. <i>Blood</i> , 2012, 120, 3163-3163. | 0.6 | 0 |
| 462 | Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. <i>Blood</i> , 2012, 120, 3769-3769. | 0.6 | 0 |
| 463 | Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. <i>Blood</i> , 2012, 120, 4234-4234. | 0.6 | 0 |
| 464 | Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib. <i>Blood</i> , 2012, 120, 3742-3742. | 0.6 | 0 |
| 465 | Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. <i>Blood</i> , 2012, 120, 2797-2797. | 0.6 | 2 |
| 466 | Isolated myeloid sarcoma without bone marrow involvement. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 66-7. | 0.3 | 1 |
| 467 | Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 266-8. | 0.3 | 0 |
| 468 | Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. <i>Leukemia and Lymphoma</i> , 2011, 52, 1372-1375. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 469 | Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients. <i>BioDrugs</i> , 2011, 25, 147-157. | 2.2 | 15 |
| 470 | Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 225-234. | 1.4 | 34 |
| 471 | Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?. <i>Cancer Letters</i> , 2011, 300, 115-121. | 3.2 | 35 |
| 472 | Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011, 118, 4554-4560. | 0.6 | 221 |
| 473 | The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS. <i>Haematologica</i> , 2011, 96, e45-e45. | 1.7 | 1 |
| 474 | Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011, 117, 5591-5599. | 0.6 | 97 |
| 475 | Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes. <i>Haematologica</i> , 2011, 96, e41-e42. | 1.7 | 13 |
| 476 | Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. <i>Haematologica</i> , 2011, 96, 1390-1391. | 1.7 | 20 |
| 477 | Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011, 96, 1457-1461. | 1.7 | 58 |
| 478 | The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). <i>Haematologica</i> , 2011, 96, e23-e24. | 1.7 | 12 |
| 479 | Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a "grey zone" at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention. <i>British Journal of Haematology</i> , 2011, 152, 119-121. | 1.2 | 9 |
| 480 | GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011, 154, 564-568. | 1.2 | 22 |
| 481 | 5-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3. <i>Leukemia</i> , 2011, 25, 736-737. | 3.3 | 6 |
| 482 | Nilotinib and dasatinib first-line: Are we ready for imatinib replacement?. <i>Leukemia Research</i> , 2011, 35, 1153-1155. | 0.4 | 0 |
| 483 | Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169. | 0.4 | 28 |
| 484 | 5-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. <i>Leukemia Research</i> , 2011, 35, 1409-1411. | 0.4 | 3 |
| 485 | Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences. <i>Leukemia Research</i> , 2011, 35, e215-e216. | 0.4 | 6 |
| 486 | A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia. <i>Annals of Hematology</i> , 2011, 90, 845-846. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 487 | Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2011, 86, 523-525. | 2.0 | 7 |
| 488 | The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 135-143. | 2.0 | 15 |
| 489 | Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2011, 35, 159-162. | 0.4 | 36 |
| 490 | Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , 2011, 35, 504-507. | 0.4 | 12 |
| 491 | Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. <i>Leukemia Research</i> , 2011, 35, e69-e70. | 0.4 | 2 |
| 492 | Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. <i>Leukemia Research</i> , 2011, 35, e91-e92. | 0.4 | 6 |
| 493 | The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2075-2087. | 0.9 | 6 |
| 494 | Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 707-717. | 0.0 | 2 |
| 495 | Bringing prognostic scores for chronic myeloid leukemia patients up to date. <i>Expert Review of Hematology</i> , 2011, 4, 373-375. | 1.0 | 1 |
| 496 | Familial occurrence of myelodysplastic syndrome with del(5q). <i>Leukemia and Lymphoma</i> , 2011, 52, 1143-1145. | 0.6 | 0 |
| 497 | LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011021. | 0.5 | 20 |
| 498 | Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. <i>Haematologica</i> , 2011, 96, 696-702. | 1.7 | 64 |
| 499 | Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e402-e403. | 0.8 | 6 |
| 500 | Management of the 2009 A/H1N1 Influenza Pandemic in Patients with Hematologic Diseases: A Prospective Experience at an Italian Center. <i>Acta Haematologica</i> , 2011, 126, 1-7. | 0.7 | 7 |
| 501 | Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). <i>Blood</i> , 2011, 118, 2756-2756. | 0.6 | 7 |
| 502 | Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. <i>Blood</i> , 2011, 118, 2770-2770. | 0.6 | 1 |
| 503 | International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2011, 118, 3132-3132. | 0.6 | 4 |
| 504 | Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. <i>Blood</i> , 2011, 118, 3783-3783. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 505 | Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453. | 0.6 | 1 |
| 506 | MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,. Blood, 2011, 118, 3793-3793. | 0.6 | 1 |
| 507 | Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. Blood, 2011, 118, 2078-2078. | 0.6 | 0 |
| 508 | Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. Blood, 2011, 118, 1682-1682. | 0.6 | 0 |
| 509 | Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786. | 0.6 | 5 |
| 510 | Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. Blood, 2011, 118, 1026-1026. | 0.6 | 0 |
| 511 | Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. Blood, 2011, 118, 4445-4445. | 0.6 | 0 |
| 512 | Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. Blood, 2011, 118, 5157-5157. | 0.6 | 0 |
| 513 | Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. Blood, 2011, 118, 5172-5172. | 0.6 | 0 |
| 514 | APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. Blood, 2011, 118, 1686-1686. | 0.6 | 0 |
| 515 | Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the "Gruppo Laziale SMPC Ph Negative". Blood, 2011, 118, 3854-3854. | 0.6 | 0 |
| 516 | Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Eledrly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. Blood, 2011, 118, 2751-2751. | 0.6 | 1 |
| 517 | Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols. Blood, 2011, 118, 4866-4866. | 0.6 | 0 |
| 518 | Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematological Oncology, 2010, 28, 89-92. | 0.8 | 12 |
| 519 | Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010, 116, 3171-3179. | 0.6 | 290 |
| 520 | Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica, 2010, 95, 853-854. | 1.7 | 49 |
| 521 | The response to imatinib and interferon- α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica, 2010, 95, 1415-1419. | 1.7 | 43 |
| 522 | Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low- and Intermediate-risk myelodysplastic syndromes with chromosome 5q deletion. European Journal of Haematology, 2010, 85, 231-235. | 1.1 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 523 | Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3â€­year followâ€­up. <i>American Journal of Hematology</i> , 2010, 85, 375-377. | 2.0 | 10 |
| 524 | Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. <i>American Journal of Hematology</i> , 2010, 85, 960-963. | 2.0 | 13 |
| 525 | Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. <i>Leukemia Research</i> , 2010, 34, 143-147. | 0.4 | 37 |
| 526 | Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 129-134. | 0.4 | 56 |
| 527 | Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment. <i>Leukemia Research</i> , 2010, 34, e122-e124. | 0.4 | 4 |
| 528 | From FAB to 2008 WHO classification: The wide heterogeneity of refractory anemia subtype among different countries. <i>Leukemia Research</i> , 2010, 34, 967-968. | 0.4 | 1 |
| 529 | Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. <i>Leukemia Research</i> , 2010, 34, e224-e225. | 0.4 | 4 |
| 530 | Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma. <i>Leukemia Research</i> , 2010, 34, e300-e301. | 0.4 | 8 |
| 531 | â€œReal-lifeâ€­results of front-line treatment with Imatinib in older patients (â‰¥65 years) with newly diagnosed chronic myelogenous leukemia. <i>Leukemia Research</i> , 2010, 34, 1472-1475. | 0.4 | 53 |
| 532 | Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance. <i>British Journal of Haematology</i> , 2010, 150, 240-242. | 1.2 | 3 |
| 533 | Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response. <i>Acta Haematologica</i> , 2010, 124, 46-48. | 0.7 | 20 |
| 534 | Clofarabine-Based Regimen as Useful Bridge Therapy for Allogeneic Transplantation in Myeloid Blast Crisis of Philadelphia-Positive Chronic Myeloid Leukemia Resistant to Imatinib and Dasatinib. <i>Acta Haematologica</i> , 2010, 124, 150-152. | 0.7 | 4 |
| 535 | Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 713-721. | 1.0 | 23 |
| 536 | Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. <i>Leukemia and Lymphoma</i> , 2010, 51, 783-788. | 0.6 | 17 |
| 537 | Nilotinib and dasatinibâ€­new 'magic bullets' for CML?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 557-558. | 12.5 | 5 |
| 538 | Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months. <i>Acta OncolÃ³gica</i> , 2010, 49, 399-400. | 0.8 | 1 |
| 539 | NF-Î²B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1157-1176. | 1.5 | 46 |
| 540 | Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. <i>Leukemia and Lymphoma</i> , 2010, 51, 1007-1014. | 0.6 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 541 | Successful Pregnancy In APL Patients Treated According to the AIDA Protocol.. Blood, 2010, 116, 1037-1037. | 0.6 | 2 |
| 542 | Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL. Blood, 2010, 116, 15-15. | 0.6 | 7 |
| 543 | Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. Blood, 2010, 116, 2293-2293. | 0.6 | 2 |
| 544 | Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. Blood, 2010, 116, 3413-3413. | 0.6 | 2 |
| 545 | Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. Blood, 2010, 116, 359-359. | 0.6 | 14 |
| 546 | Comorbidities Indexes In Patients Treated with 5-Azacididine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation. Blood, 2010, 116, 606-606. | 0.6 | 1 |
| 547 | Abstract 1805: Improving on Imatinib for targeted therapy of chronic myeloid leukemia: First line treatment with Nilotinib 800 mg daily results in unprecedentedly high rate of rapid, deep and stable molecular responses - Results of a phase 2 trial of the GIMEMA CML working party. , 2010, , . | | 0 |
| 548 | Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features. Blood, 2010, 116, 4976-4976. | 0.6 | 0 |
| 549 | Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270. | 0.6 | 0 |
| 550 | First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, Deep and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2010, 116, 2720-2720. | 0.6 | 0 |
| 551 | Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia: What Have We Learned Over the Last Twenty Years?.. Blood, 2010, 116, 3423-3423. | 0.6 | 0 |
| 552 | Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. Blood, 2010, 116, 2279-2279. | 0.6 | 0 |
| 553 | Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.. Blood, 2010, 116, 3409-3409. | 0.6 | 2 |
| 554 | Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features. Blood, 2010, 116, 3077-3077. | 0.6 | 0 |
| 555 | Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q). Blood, 2010, 116, 2927-2927. | 0.6 | 0 |
| 556 | Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281. | 0.6 | 0 |
| 557 | Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study. Blood, 2010, 116, 4953-4953. | 0.6 | 0 |
| 558 | BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 559 | A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. <i>Blood</i> , 2010, 116, 5065-5065. | 0.6 | 0 |
| 560 | One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (â‰¥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, <i>ClinicalTrials.Gov</i> NCT 00858806.. <i>Blood</i> , 2010, 116, 3412-3412. | 0.6 | 0 |
| 561 | Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. <i>Blood</i> , 2010, 116, 2273-2273. | 0.6 | 0 |
| 562 | The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.. <i>Blood</i> , 2010, 116, 3399-3399. | 0.6 | 0 |
| 563 | Imatinib In Very Elderly CML Patients: What Can We Achieve?.. <i>Blood</i> , 2010, 116, 1229-1229. | 0.6 | 0 |
| 564 | Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. <i>Blood</i> , 2010, 116, 2294-2294. | 0.6 | 1 |
| 565 | Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome. <i>Clinical Management Issues</i> , 2010, 4, 7-11. | 0.3 | 0 |
| 566 | Nilotinib: selective inhibitor as second-line therapy. <i>Clinical Management Issues</i> , 2010, 4, 3-5. | 0.3 | 0 |
| 567 | Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib. <i>Clinical Management Issues</i> , 2010, 4, 9-13. | 0.3 | 0 |
| 568 | Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance. <i>Leukemia and Lymphoma</i> , 2009, 50, 848-850. | 0.6 | 4 |
| 569 | Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2009, 9, 21-28. | 0.2 | 13 |
| 570 | Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. <i>Clinical Cancer Research</i> , 2009, 15, 1059-1063. | 3.2 | 28 |
| 571 | Comorbidities and FLT3â€“TD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients. <i>Hematological Oncology</i> , 2009, 27, 148-153. | 0.8 | 38 |
| 572 | Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient. <i>International Journal of Hematology</i> , 2009, 89, 720-721. | 0.7 | 6 |
| 573 | Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. <i>International Journal of Hematology</i> , 2009, 90, 486-491. | 0.7 | 2 |
| 574 | Isolated molecular relapse in FIP1L1-PDGFRÎ± hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1161-1163. | 1.1 | 3 |
| 575 | Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 195-197. | 1.1 | 6 |
| 576 | Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?. <i>Bone Marrow Transplantation</i> , 2009, 44, 331-332. | 1.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 577 | Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature. <i>Leukemia Research</i> , 2009, 33, 200-201. | 0.4 | 2 |
| 578 | Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. <i>Leukemia Research</i> , 2009, 33, 391-394. | 0.4 | 6 |
| 579 | Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. <i>Leukemia Research</i> , 2009, 33, 645-648. | 0.4 | 2 |
| 580 | WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?. <i>Leukemia Research</i> , 2009, 33, e93-e94. | 0.4 | 5 |
| 581 | The metabolic consequences of imatinib mesylate: Changes on glucose, lipidic and bone metabolism. <i>Leukemia Research</i> , 2009, 33, 871-875. | 0.4 | 22 |
| 582 | Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. <i>Leukemia Research</i> , 2009, 33, e134-e136. | 0.4 | 14 |
| 583 | Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?. <i>Leukemia Research</i> , 2009, 33, 1450-1451. | 0.4 | 1 |
| 584 | Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by Frenchâ€“Americanâ€“British and World Health Organisation classifications. <i>Leukemia and Lymphoma</i> , 2009, 50, 841-843. | 0.6 | 1 |
| 585 | Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. <i>Leukemia and Lymphoma</i> , 2009, 50, 387-391. | 0.6 | 50 |
| 586 | Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009, 50, 114-118. | 0.6 | 9 |
| 587 | The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009, 94, 205-212. | 1.7 | 73 |
| 588 | Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434. | 0.6 | 59 |
| 589 | Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 4933-4938. | 0.6 | 203 |
| 590 | Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL. <i>Current Drug Targets</i> , 2009, 10, 530-536. | 1.0 | 6 |
| 591 | The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , 2009, 114, 2192-2192. | 0.6 | 3 |
| 592 | Chronic Myeloid Leukemia (CML) Patients with â€œSuboptimalâ€•Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to â€œOptimalâ€•Responders: A GIMEMA CML WORKING PARTY Analysis.. <i>Blood</i> , 2009, 114, 2196-2196. | 0.6 | 3 |
| 593 | Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. <i>Blood</i> , 2009, 114, 2205-2205. | 0.6 | 8 |
| 594 | BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009, 114, 648-648. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 595 | Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860. | 0.6 | 3 |
| 596 | ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.. Blood, 2009, 114, 4160-4160. | 0.6 | 0 |
| 597 | The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.. Blood, 2009, 114, 1124-1124. | 0.6 | 0 |
| 598 | Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.. Blood, 2009, 114, 1019-1019. | 0.6 | 0 |
| 599 | Old Age Affects Survival but Not Response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib (IM): A Study of the GIMEMA CML WORKING PARTY.. Blood, 2009, 114, 1118-1118. | 0.6 | 1 |
| 600 | Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?. Blood, 2009, 114, 4271-4271. | 0.6 | 0 |
| 601 | Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.. Blood, 2009, 114, 4545-4545. | 0.6 | 0 |
| 602 | Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.. Blood, 2009, 114, 4985-4985. | 0.6 | 0 |
| 603 | Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.. Blood, 2009, 114, 2763-2763. | 0.6 | 1 |
| 604 | Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. Blood, 2009, 114, 2211-2211. | 0.6 | 0 |
| 605 | Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. Blood, 2009, 114, 1777-1777. | 0.6 | 0 |
| 606 | Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 European Leukemia Net (ELN) Criteria.. Blood, 2009, 114, 3302-3302. | 0.6 | 1 |
| 607 | Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. Leukemia Research, 2008, 32, 177-180. | 0.4 | 15 |
| 608 | Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. Leukemia Research, 2008, 32, 255-261. | 0.4 | 13 |
| 609 | Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. Leukemia Research, 2008, 32, 514-516. | 0.4 | 33 |
| 610 | Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases. Leukemia Research, 2008, 32, 519-520. | 0.4 | 27 |
| 611 | Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. Leukemia Research, 2008, 32, 353-355. | 0.4 | 8 |
| 612 | Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. Leukemia Research, 2008, 32, 835-836. | 0.4 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 613 | Ocular side effects in chronic myeloid leukemia patients treated with imatinib. <i>Leukemia Research</i> , 2008, 32, 1022-1025. | 0.4 | 45 |
| 614 | Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. <i>Leukemia Research</i> , 2008, 32, 1626-1628. | 0.4 | 49 |
| 615 | Pregnancy in patients with myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2008, 32, 1605-1607. | 0.4 | 6 |
| 616 | Liposomal daunorubicin <i>versus</i> standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 681-689. | 1.2 | 54 |
| 617 | Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2008, 49, 994-997. | 0.6 | 8 |
| 618 | Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 2328-2332. | 0.6 | 14 |
| 619 | Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 2008, 120, 104-107. | 0.7 | 18 |
| 620 | Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008, 93, 1792-1796. | 1.7 | 91 |
| 621 | Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. <i>Haematologica</i> , 2008, 93, 1918-1920. | 1.7 | 17 |
| 622 | Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008, 26, 106-111. | 0.8 | 48 |
| 623 | Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems. <i>Leukemia and Lymphoma</i> , 2008, 49, 1292-1296. | 0.6 | 10 |
| 624 | Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- α : 5-year outcome. <i>Haematologica</i> , 2008, 93, 770-774. | 1.7 | 53 |
| 625 | Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib. <i>OncoTargets and Therapy</i> , 2008, 1, 49. | 1.0 | 2 |
| 626 | High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008, 112, 181-181. | 0.6 | 19 |
| 627 | Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD). <i>Blood</i> , 2008, 112, 5237-5237. | 0.6 | 1 |
| 628 | Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. <i>Blood</i> , 2008, 112, 4288-4288. | 0.6 | 0 |
| 629 | Dasatinib in the Treatment of CML Patients Aged \geq 60 Years Resistant/Intolerant to Imatinib. <i>Blood</i> , 2008, 112, 4253-4253. | 0.6 | 0 |
| 630 | Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.. <i>Blood</i> , 2008, 112, 1949-1949. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 631 | Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2008, 112, 4281-4281. | 0.6 | 1 |
| 632 | Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria. <i>Blood</i> , 2008, 112, 5097-5097. | 0.6 | 0 |
| 633 | Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2008, 112, 3983-3983. | 0.6 | 0 |
| 634 | Treatment with Imatinib in Very Elderly (> 75 Years) CML Patients.. <i>Blood</i> , 2008, 112, 1096-1096. | 0.6 | 0 |
| 635 | Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: A possible manifestation of retinoic acid syndrome. <i>Leukemia and Lymphoma</i> , 2007, 48, 833-834. | 0.6 | 2 |
| 636 | Refractory Anaemia with Excess of Blasts in Transformation Re-Evaluated with the WHO Criteria: Identification of Subgroups with Different Survival. <i>Acta Haematologica</i> , 2007, 117, 221-225. | 0.7 | 3 |
| 637 | Late Relapses in Acute Promyelocytic Leukaemia. <i>Acta Haematologica</i> , 2007, 117, 106-108. | 0.7 | 17 |
| 638 | Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy. <i>Acta Haematologica</i> , 2007, 118, 162-164. | 0.7 | 10 |
| 639 | Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 1273-1274. | 1.7 | 49 |
| 640 | Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignancies. <i>Haematologica</i> , 2007, 92, 666-673. | 1.7 | 30 |
| 641 | Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. <i>Leukemia Research</i> , 2007, 31, 1770-1772. | 0.4 | 58 |
| 642 | Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia</i> , 2007, 21, 79-83. | 3.3 | 108 |
| 643 | Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid. <i>Annals of Hematology</i> , 2007, 86, 295-297. | 0.8 | 2 |
| 644 | Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. <i>Annals of Hematology</i> , 2007, 86, 263-270. | 0.8 | 21 |
| 645 | In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.. <i>Blood</i> , 2007, 110, 1934-1934. | 0.6 | 2 |
| 646 | Cocaine abuse may influence the response to imatinib in CML patients. <i>Haematologica</i> , 2007, 92, e41-e42. | 1.7 | 3 |
| 647 | Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , 2007, 110, 4564-4564. | 0.6 | 0 |
| 648 | JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. <i>Blood</i> , 2007, 110, 4652-4652. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 649 | Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Imatinib: Introducing the Concept of Confirmed Molecular Response.. Blood, 2007, 110, 1933-1933. | 0.6 | 5 |
| 650 | Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.. Blood, 2007, 110, 4609-4609. | 0.6 | 0 |
| 651 | Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.. Blood, 2007, 110, 4636-4636. | 0.6 | 0 |
| 652 | Atypical Chronic Myeloid Leukaemia with CD117-Positive Blast Cells Treated with Imatinib: A Report of Two Cases. Acta Haematologica, 2006, 116, 211-212. | 0.7 | 1 |
| 653 | Role of \hat{I}^3 -glutamyl cysteine synthetase (\hat{I}^3 -GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias. Clinica Chimica Acta, 2006, 365, 342-345. | 0.5 | 9 |
| 654 | Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes. Leukemia, 2006, 20, 1978-1988. | 3.3 | 31 |
| 655 | Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. Leukemia Research, 2006, 30, 178-182. | 0.4 | 17 |
| 656 | Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+ CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leukemia Research, 2006, 30, 1577-1579. | 0.4 | 31 |
| 657 | Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer, 2006, 107, 1008-1013. | 2.0 | 28 |
| 658 | Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. Clinical Cancer Research, 2006, 12, 3037-3042. | 3.2 | 90 |
| 659 | Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Annals of Oncology, 2006, 17, 281-285. | 0.6 | 30 |
| 660 | Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 1979-1979. | 0.6 | 10 |
| 661 | Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie) Tj ETQq1 1 0.784314 rgBT /Overl... Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2006, 108, 4776-4776. | 0.6 | 3 |
| 662 | Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.. Blood, 2006, 108, 3595-3595. | 0.6 | 0 |
| 663 | Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.. Blood, 2006, 108, 2156-2156. | 0.6 | 0 |
| 664 | Quality of Life in Elderly Patients with Acute Myeloid Leukemia.. Blood, 2006, 108, 3320-3320. | 0.6 | 0 |
| 665 | Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. Blood, 2006, 108, 2158-2158. | 0.6 | 0 |
| 666 | Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.. Blood, 2006, 108, 2667-2667. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 667 | Identification of risk factors in atypical chronic myeloid leukemia. <i>Haematologica</i> , 2006, 91, 1566-8. | 1.7 | 78 |
| 668 | Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. <i>Leukemia Research</i> , 2005, 29, 33-39. | 0.4 | 11 |
| 669 | Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. <i>Leukemia Research</i> , 2005, 29, 287-291. | 0.4 | 20 |
| 670 | Myelodysplastic syndromes in patients under 50 years old: a single institution experience. <i>Leukemia Research</i> , 2005, 29, 749-754. | 0.4 | 23 |
| 671 | BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. <i>Bone Marrow Transplantation</i> , 2005, 36, 83-84. | 1.3 | 7 |
| 672 | Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. <i>Leukemia</i> , 2005, 19, 287-289. | 3.3 | 2 |
| 673 | Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. <i>European Journal of Haematology</i> , 2005, 74, 89-90. | 1.1 | 44 |
| 674 | Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. <i>European Journal of Haematology</i> , 2005, 74, 121-123. | 1.1 | 62 |
| 675 | Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?. <i>European Journal of Haematology</i> , 2005, 75, 89-90. | 1.1 | 9 |
| 676 | Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management. <i>European Journal of Haematology</i> , 2005, 75, 396-400. | 1.1 | 11 |
| 677 | Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2005, 106, 1098-1098. | 0.6 | 4 |
| 678 | Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2005, 106, 885-885. | 0.6 | 1 |
| 679 | Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.. <i>Blood</i> , 2005, 106, 887-887. | 0.6 | 0 |
| 680 | Acute Myeloid Leukemia Secondary to a Myelodysplastic Syndrome with t(3;3) (q21;q26) in an HIV Patient Treated with Chemotherapy and Highly Active Antiretroviral Therapy. <i>Acta Haematologica</i> , 2004, 111, 160-162. | 0.7 | 9 |
| 681 | Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. <i>Leukemia</i> , 2004, 18, 182-182. | 3.3 | 17 |
| 682 | Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. <i>Leukemia</i> , 2004, 18, 361-362. | 3.3 | 19 |
| 683 | Paroxysmal cold haemoglobinuria as a tardive complication of idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2004, 73, 304-306. | 1.1 | 9 |
| 684 | Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. <i>Leukemia Research</i> , 2004, 28, 1165-1169. | 0.4 | 100 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 685 | Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 1995-1999. | 0.6 | 225 |
| 686 | Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.. <i>Blood</i> , 2004, 104, 4693-4693. | 0.6 | 1 |
| 687 | Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. <i>Haematologica</i> , 2004, 89, 29-33. | 1.7 | 31 |
| 688 | Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. <i>Haematologica</i> , 2004, 89, ECR11. | 1.7 | 6 |
| 689 | Recurrent Sweet's syndrome in acute myeloid leukemia successfully treated with amphotericin B. <i>Haematologica</i> , 2004, 89, ELT04. | 1.7 | 1 |
| 690 | Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2004, 89, 615-7. | 1.7 | 13 |
| 691 | Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. <i>Haematologica</i> , 2004, 89, 866-8. | 1.7 | 24 |
| 692 | Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia. <i>Haematologica</i> , 2004, 89, ECR20. | 1.7 | 0 |
| 693 | Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation. <i>European Journal of Haematology</i> , 2003, 70, 190-192. | 1.1 | 24 |
| 694 | Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. <i>British Journal of Haematology</i> , 2003, 120, 266-270. | 1.2 | 47 |
| 695 | Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. <i>Leukemia</i> , 2003, 17, 925-930. | 3.3 | 38 |
| 696 | Hypermethylation of CpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis. <i>Leukemia</i> , 2003, 17, 919-924. | 3.3 | 55 |
| 697 | The importance of molecular monitoring in acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 503-520. | 0.7 | 27 |
| 698 | Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 653-670. | 0.7 | 4 |
| 699 | Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003, 102, 1035-1041. | 0.6 | 74 |
| 700 | Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated "sanctuary"? <i>Leukemia</i> , 2002, 16, 1127-1130. | 3.3 | 32 |
| 701 | Therapy-related myelodysplastic syndrome"acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. <i>Blood</i> , 2002, 99, 822-824. | 0.6 | 125 |
| 702 | Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen. <i>European Journal of Haematology</i> , 2002, 68, 1-3. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 703 | Conservative treatment for patients over 80 years with acute myelogenous leukemia. American Journal of Hematology, 2002, 71, 256-259. | 2.0 | 13 |
| 704 | Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2002, 116, 576-581. | 1.2 | 80 |
| 705 | Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. British Journal of Haematology, 2002, 116, 299-307. | 1.2 | 23 |
| 706 | Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?. British Journal of Haematology, 2002, 118, 438-441. | 1.2 | 22 |
| 707 | Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia. Leukemia, 2002, 16, 1293-1301. | 3.3 | 29 |
| 708 | Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 2002, 16, 2185-2189. | 3.3 | 176 |
| 709 | AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. Haematologica, 2002, 87, ELT12. | 1.7 | 8 |
| 710 | Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. British Journal of Haematology, 2002, 116, 299-307. | 1.2 | 10 |
| 711 | Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. Annals of Hematology, 2001, 80, 614-616. | 0.8 | 16 |
| 712 | Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. British Journal of Haematology, 2001, 113, 136-142. | 1.2 | 16 |
| 713 | Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction. Leukemia and Lymphoma, 2000, 36, 539-541. | 0.6 | 2 |
| 714 | Granulocytic Sarcoma with Breast and Skin Presentation: A Report of a Case Successfully Treated by Local Radiation and Systemic Chemotherapy. Acta Haematologica, 2000, 104, 34-37. | 0.7 | 16 |
| 715 | Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. British Journal of Haematology, 1999, 106, 133-141. | 1.2 | 21 |
| 716 | Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. Leukemia, 1999, 13, 514-517. | 3.3 | 17 |
| 717 | The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. Annals of Oncology, 1997, 8, 1273-1275. | 0.6 | 25 |
| 718 | Acute promyelocytic leukemia: pathophysiology and clinical results update. , 0, , 131-140. | | 0 |